FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283542> ?p ?o ?g. }

• W4379283542 endingPage "2067" @default.
• W4379283542 startingPage "2067" @default.
• W4379283542 abstract "2067 Background: Novel therapeutic strategies are urgently needed in newly-diagnosed glioblastoma (GBM). Ibrutinib, an oral small molecule inhibitor of BTK, is currently being investigated for several B-cell malignancies and solid tumors. Preclinical evidence suggests ibrutinib in inhibiting cancer stem cell in glioblastoma. We sought to investigate the safety and tolerability of ibrutinib in nGBM. Methods: A non-randomized, prospective phase I trial was conducted in nGBM patients with Karnofsky performance status ≥70% and normal organ function, who received standard of care chemoradiation plus ibrutinib in a 3+3 dose-escalation design (level 1: 420 mg daily, level 2: 560 mg daily, level -1: 280 mg daily). Primary study objective was to determine maximum tolerated dose (MTD) of ibrutinib in combination with radiotherapy (RT) of 60 Gy over 6 weeks with/without 75 mg/m 2 of temozolomide (TMZ). Secondary objective was to determine safety, overall survival (OS), and progression-free survival. Results: 26 patients were enrolled, with 12 (46%) females. Median age was 61.5 years (range 76-22). 15 (58%) patients were MGMT methylated and 11 (42%) were unmethylated. Dose-limiting toxicities (DLTs) were observed at all dose levels of ibrutinib plus RT (ibru+RT) cohort. MTD of ibrutinib was noted to be 420 mg daily with RT+TMZ. All MGMT methylated and 2 unmethylated patients received ibrutinib+RT+TMZ. Remaining 9 unmethylated received ibru+RT. In ibru+RT+TMZ, median cycles of TMZ were 4 (range 0-6) and of ibrutinib were 3 (range 0-26). EGFR amplification status was available for 22 patients, of which 8 (36%) were amplified. Survival outcomes are described, stratified using log-rank test. Conclusions: 420 mg of Ibrutinib daily is safe and feasible in combination with TMZ and radiation in nGBM. Outcomes of ibrutinib appears promising compared to historical survival data in the MGMT methylated cohorts. Further trials are planned. Clinical trial information: NCT03535350 . [Table: see text]" @default.
• W4379283542 created "2023-06-05" @default.
• W4379283542 creator A5007125727 @default.
• W4379283542 creator A5016811839 @default.
• W4379283542 creator A5033599840 @default.
• W4379283542 creator A5035416012 @default.
• W4379283542 creator A5054741163 @default.
• W4379283542 creator A5058440874 @default.
• W4379283542 creator A5064002081 @default.
• W4379283542 creator A5075490964 @default.
• W4379283542 creator A5079216912 @default.
• W4379283542 creator A5085460226 @default.
• W4379283542 creator A5087295298 @default.
• W4379283542 date "2023-06-01" @default.
• W4379283542 modified "2023-10-14" @default.
• W4379283542 title "Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report." @default.
• W4379283542 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.2067" @default.
• W4379283542 hasPublicationYear "2023" @default.
• W4379283542 type Work @default.
• W4379283542 citedByCount "0" @default.
• W4379283542 crossrefType "journal-article" @default.
• W4379283542 hasAuthorship W4379283542A5007125727 @default.
• W4379283542 hasAuthorship W4379283542A5016811839 @default.
• W4379283542 hasAuthorship W4379283542A5033599840 @default.
• W4379283542 hasAuthorship W4379283542A5035416012 @default.
• W4379283542 hasAuthorship W4379283542A5054741163 @default.
• W4379283542 hasAuthorship W4379283542A5058440874 @default.
• W4379283542 hasAuthorship W4379283542A5064002081 @default.
• W4379283542 hasAuthorship W4379283542A5075490964 @default.
• W4379283542 hasAuthorship W4379283542A5079216912 @default.
• W4379283542 hasAuthorship W4379283542A5085460226 @default.
• W4379283542 hasAuthorship W4379283542A5087295298 @default.
• W4379283542 hasConcept C126322002 @default.
• W4379283542 hasConcept C143998085 @default.
• W4379283542 hasConcept C197934379 @default.
• W4379283542 hasConcept C2777389519 @default.
• W4379283542 hasConcept C2777938653 @default.
• W4379283542 hasConcept C2778375690 @default.
• W4379283542 hasConcept C2778461978 @default.
• W4379283542 hasConcept C2779878957 @default.
• W4379283542 hasConcept C31760486 @default.
• W4379283542 hasConcept C509974204 @default.
• W4379283542 hasConcept C535046627 @default.
• W4379283542 hasConcept C71924100 @default.
• W4379283542 hasConceptScore W4379283542C126322002 @default.
• W4379283542 hasConceptScore W4379283542C143998085 @default.
• W4379283542 hasConceptScore W4379283542C197934379 @default.
• W4379283542 hasConceptScore W4379283542C2777389519 @default.
• W4379283542 hasConceptScore W4379283542C2777938653 @default.
• W4379283542 hasConceptScore W4379283542C2778375690 @default.
• W4379283542 hasConceptScore W4379283542C2778461978 @default.
• W4379283542 hasConceptScore W4379283542C2779878957 @default.
• W4379283542 hasConceptScore W4379283542C31760486 @default.
• W4379283542 hasConceptScore W4379283542C509974204 @default.
• W4379283542 hasConceptScore W4379283542C535046627 @default.
• W4379283542 hasConceptScore W4379283542C71924100 @default.
• W4379283542 hasIssue "16_suppl" @default.
• W4379283542 hasLocation W43792835421 @default.
• W4379283542 hasOpenAccess W4379283542 @default.
• W4379283542 hasPrimaryLocation W43792835421 @default.
• W4379283542 hasRelatedWork W2000054321 @default.
• W4379283542 hasRelatedWork W2034544297 @default.
• W4379283542 hasRelatedWork W2107697672 @default.
• W4379283542 hasRelatedWork W2162934203 @default.
• W4379283542 hasRelatedWork W2380706439 @default.
• W4379283542 hasRelatedWork W2410936318 @default.
• W4379283542 hasRelatedWork W2502883985 @default.
• W4379283542 hasRelatedWork W2566967253 @default.
• W4379283542 hasRelatedWork W2789023463 @default.
• W4379283542 hasRelatedWork W4295758394 @default.
• W4379283542 hasVolume "41" @default.
• W4379283542 isParatext "false" @default.
• W4379283542 isRetracted "false" @default.
• W4379283542 workType "article" @default.